Quark Pharmaceuticals

Quark Pharmaceuticals is a biotechnology company that has been making waves since its establishment in 1994. The company has focused on developing the BiFAR technology platform for identifying new functional target genes and proteins. This innovative approach, patented by Quark, involves high-throughput gene inactivation combined with microarray detection of the functional genes responsible for phenotypes of interest. This groundbreaking technique has been instrumental in advancing gene discovery programs targeting serious diseases with significant unmet medical needs. With the rise of siRNA technology, Quark's approach is gaining traction and is rapidly becoming the preferred method for functional studies across the industry. The company has forged impactful collaborations with large pharmaceutical partners to utilize the BiFAR platform in driving genetic advancements. Notably, Quark secured a $10.00M Venture Round investment on 01 June 2010, which underscores the confidence investors have in the company's technology and potential impact. Through their pioneering efforts and innovative technology, Quark is dedicated to shaping a healthier future and addressing unmet medical needs in the field of genetics.